Showing 20 of 200 recruiting trials for “large-granular-lymphocyte-leukemia”
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
👨⚕️ Mazyar Shadman, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started May 2023View details ↗
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia
RecruitingNCT06334835 ↗
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
👨⚕️ Ryan D. Cassaday, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Mar 2023View details ↗
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
👨⚕️ Nelson Hamerschlak, MD, PhH, Hospital Israelita Albert Einstein📍 1 site📅 Started Feb 2023View details ↗
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
Co-administration of CART22-65s and huCART19 for B-ALL
Pilot Imaging Study of Leukemia
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
👨⚕️ Janine Stutterheim, Dr, Princess Maxima Center for Pediatric Oncology in The Netherlands📍 112 sites📅 Started Dec 2022View details ↗
RecruitingNCT05929976 ↗
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
CAV Regimen for R/R Ph- B-ALL
Vaccine Responses in Patients With B Cell Malignancies
👨⚕️ Adrian U Wiestner, M.D., National Heart, Lung, and Blood Institute (NHLBI)📍 1 site📅 Started Sep 2022View details ↗
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →